Welcome to LookChem.com Sign In|Join Free

CAS

  • or
D-Tyrosinol, also known as dehydro dehydrophenylalanine, is a chiral bioactive compound belonging to the class of tyrosine derivatives. It is the natural form of this molecule, found in various plant sources such as Lathyrus sativus and Lathyrus cicera. D-Tyrosinol has been recognized for its potential biological activities, including antioxidant and anti-inflammatory properties, and plays a role in the biosynthesis of various natural products. This makes D-Tyrosinol a promising candidate for applications in the pharmaceutical and nutraceutical industries.

58889-64-8

Post Buying Request

58889-64-8 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

58889-64-8 Usage

Uses

Used in Pharmaceutical Industry:
D-Tyrosinol is used as a bioactive compound for its potential therapeutic applications due to its antioxidant and anti-inflammatory properties. These properties can contribute to the development of treatments for various conditions where oxidative stress and inflammation are factors.
Used in Nutraceutical Industry:
D-Tyrosinol is used as a functional ingredient for its health-promoting benefits. Its presence in dietary supplements and fortified foods can support consumers' health by providing antioxidant and anti-inflammatory support, which may contribute to overall well-being and the prevention of certain diseases.
Used in Biosynthesis Research:
D-Tyrosinol is used as a key intermediate in the biosynthesis of various natural products. Its role in this process is crucial for the development of new pharmaceuticals and nutraceuticals derived from natural sources, potentially leading to the discovery of novel bioactive compounds with unique health benefits.

Check Digit Verification of cas no

The CAS Registry Mumber 58889-64-8 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,8,8,8 and 9 respectively; the second part has 2 digits, 6 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 58889-64:
(7*5)+(6*8)+(5*8)+(4*8)+(3*9)+(2*6)+(1*4)=198
198 % 10 = 8
So 58889-64-8 is a valid CAS Registry Number.
InChI:InChI=1/C9H13NO2/c10-8(6-11)5-7-1-3-9(12)4-2-7/h1-4,8,11-12H,5-6,10H2/t8-/m1/s1

58889-64-8SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 13, 2017

Revision Date: Aug 13, 2017

1.Identification

1.1 GHS Product identifier

Product name 4-[(2R)-2-amino-3-hydroxypropyl]phenol

1.2 Other means of identification

Product number -
Other names D-TYROSINOL

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:58889-64-8 SDS

58889-64-8Relevant articles and documents

Illuminating a Dark Kinase: Structure-Guided Design, Synthesis, and Evaluation of a Potent Nek1 Inhibitor and Its Effects on the Embryonic Zebrafish Pronephros

Baumann, Georg,Meckel, Tobias,B?hm, Kevin,Shih, Yung-Hsin,Dickhaut, Mirco,Reichardt, Torben,Pilakowski, Johannes,Pehl, Ulrich,Schmidt, Boris

, p. 1265 - 1282 (2021/04/12)

NIMA-related kinase 1 (Nek1) has lately garnered attention for its widespread function in ciliogenesis, apoptosis, and the DNA-damage response. Despite its involvement in various diseases and its potential as a cancer drug target, no directed medicinal chemistry efforts toward inhibitors against this dark kinase are published. Here, we report the structure-guided design of a potent small-molecule Nek1 inhibitor, starting from a scaffold identified by kinase cross-screening analysis. Seven lead compounds were identified in silico and evaluated for their inhibitory activity. The top compound, 10f, was further profiled for efficacy, toxicity, and bioavailability in a zebrafish polycystic kidney disease model. Administration of 10f caused the expansion of fluorescence-labeled proximal convoluted tubules, supporting our hypothesis that Nek1-inhibition causes cystic kidneys in zebrafish embryos. Compound 10f displayed insignificant inhibition in 48 of 50 kinases in a selectivity test panel. The findings provide a powerful tool to further elucidate the function and pharmacology of this neglected kinase.

Tyropeptins A and B, new proteasome inhibitors produced by Kitasatospora sp. MK993-dF2 II. Structure determination and synthesis

Momose, Isao,Sekizawa, Ryuichi,Hirosawa, Sehei,Ikeda, Daishiro,Naganawa, Hiroshi,Inuma, Hironobu,Takeuchi, Tomio

, p. 1004 - 1012 (2007/10/03)

The structures of tyropeptins A and B, new proteasome inhibitors produced by Kitasatospora sp. MK993-dF2, were determined by analysis of various NMR experiments. The 1H and 13C NMR of tyropeptins were complicated due to the presence of an aldehyde group. Therefore, tyropeptins were converted to their alcohols by sodium borohydride. These alcohol derivatives gave assignable NMR spectra. The stereochemistry of tyropeptins were determined by analysis of acid hydrolysis products from tyropeptins, and further confirmed by the total synthesis. The structures of tyropeptins A and B were found to be isovaleryl-L-tyrosyl-L-valyl-DL-tyrosinal and n-butyryl-L-tyrosyl-L-leucyl-DL-tyrosinal, respectively.

New 1,4-anthracene-9,10-dione derivatives as potential anticancer agents

Zagotto,Supino,Favini,Moro,Palumbo

, p. 1 - 5 (2007/10/03)

The amino-substituted anthracene-9,10-dione (9,10-anthraquinone) derivatives represent one of the most important classes of potential anticancer agents. To better understand the basic rules governing DNA sequence specificity, we have recently synthesized a new class of d- and l- aminoacyl-anthraquinone derivatives. We have tested these new compounds as cytotoxic agents, and we have correlated their activity with the configuration of the chiral aminoacyl moiety. Molecular modeling studies have been performed to compare the test drugs in terms of steric overlapping. (C) 2000 Elsevier Science S.A.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 58889-64-8